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ABSTRACT
Hyperparathyroidism during pregnancy is diagnosed in 0.5–1.4% women and poses a serious challenge. Symptoms of 
primary hyperparathyroidism (PHP), namely fatigue, lethargy and proximal muscle weakness, are unspecific and could be 
mistaken as complaints naturally present during pregnancy. Thus, diagnosis is usually delayed. Moreover, the complica-
tions of PHP are very common. They occur in 67% of mothers and even in up to 80% of progeny. Appropriate management 
is a matter of debate. According to clinical symptoms, biochemical evaluation and trimester of pregnancy an operation 
or conservative management should be introduced. The recognition and understanding of the illness is therefore vital. 
Due to the lack of unequivocal guidelines concerning pregnancy and PHP, in this review we will analyze recent findings 
to facilitate proper proceedings. 
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INTRODUCTION
Calcium plays a vital role in body homeostasis. Calcium- 
-phosphorus balance is mainly regulated via parathormone, 
calcitonin and vitamin D. The most common reasons of 
hypercalcemia are primary hyperparathyroidism (PHP) and 
neoplasms. It is estimated that PHP occurs with an inci-
dence of 1.4% of the general population. However, more 
than 80% of PHP cases remains asymptomatic in both the 
pregnant and nonpregnant patients and are diagnosed 
incidentally by review of laboratory data. This disease is 
present in 0.5–1.4% pregnant women. In 85% the cause of 
the illness is parathyroid adenoma [1]. Symptoms of PHP, 
namely fatigue, lethargy and proximal muscle weakness, are 
unspecific and could be mistaken as complaints naturally 
present during pregnancy [2]. Additionally, physiological 
changes which occur in women’s body in that special time 
hamper the diagnostics of calcium-phosphorus balance 
impairment. Hypoalbuminemia, increased filtration rate and 
active transport of calcium via placenta, reduces the concen-
tration of total calcium in the serum. Estradiol decreases the 
amount of parathormone (PTH). As a result, hypercalcemia in 
a pregnant state poses a real challenge for the clinician [3]. 
Moreover, the complications of PHP are very common. 
They occur in 67% of mothers and even in up to 80% of 
progeny [4]. Interestingly, neonatal tetany is claimed to be 
the most common symptom of hyperparathyroidism while 
pregnancy [5]. It is a real danger for both the woman and 
her child. Appropriate management is a matter of debate. 
According to clinical symptoms, biochemical evaluation 
and trimester of pregnancy an operation or conservative 
management should be introduced [6, 7]. The recognition 
and understanding of the illness is therefore vital. Due to 
the lack of unequivocal guidelines concerning pregnancy 
and PHP, we would like to present a review of literature il-
lustrated with two clinical cases in which PHP was diagnosed 
in completely different circumstances, though ended up 
with various pregnancy outcomes. 
First patient
A 29-years-old patient in the 21st week of her second 
pregnancy was admitted to the hospital due to a suspected 
relapse of Graves’ disease and possible adrenal dysfunc-
tion. In the 7th week of present pregnancy she complained 
about weakness, abdominal pains and vertigo. Addition-
271
Hanna Komarowska et al., Hyperparathyroidism in pregnancy
www. journals.viamedica.pl/ginekologia_polska
ally, the endocrinologist noted gradual drop in the thyroid 
stimulating hormone (TSH) values from 0.05 µU/mL (the 
10th week) to 0.0047 µU/mL (the 13th week) with a rise of 
Ft3 to 6.96 pmol/L, and introduced a treatment with a low 
dose of thiamazole. He also performed tests for adrenal 
insufficiency. The results were inconclusive (Tab. 1), but the 
hydrocortisone treatment was introduced. After hydrocor-
tisone supplementation the symptoms alleviated. Patient’s 
complaints about dizziness reoccurred with an attempt to 
reduce the doses of steroids. Thyroid stimulating hormone 
receptor antibody (TRAb) levels were within normal value. 
Past medical records revealed Graves’ disease treated suc-
cessfully with antithyroid drugs 10 years earlier.
Upon admission to the hospital, the physical examina-
tion did not reveal any abnormalities. She weighed 59 kg 
with the height of 165 cm. Her blood pressure was 110/75, 
while body temperature — 36.6°C. The uterus was palpable 
2 cm below umbilicus. An obstetrical ultrasound confirmed 
a live single intrauterine gestation. The patient complained 
about heart palpitations. The diagnostics conducted af-
ter discontinuation of glicocorticosteroids and antithyroid 
Table 1. Results of the laboratory investigations for the first patient
Week of pregnancy 13th 21th 25th
Cortysole morning
(171–536 nmol/L) 345.4 767
Cortysole afternoon
(64–327 nmol/L) 143 335
ACTH
(5.0–60.0 pg/mL) 2.34 12
Sodium
(135–145 mmol/L) 136 135
Potassium
(3.50–5.10 mmol/L) 5.56 4.85
TSH
(0.27–4.20 μU/mL) 0.0047 1.57
FT3
(3.93–7.70 pmol/L) 6.96 4.3
FT4
(11.5–21.0 pmol/L) 11.79
Calcium total
(8.80–10.20 mg/dL) 11.0 11.67 8.9
Calcium ionized
(4.2–5.2 mg/dL) 5.8 4.7
Phosphorus serum
(2.70–4.50 mg/dl) 3.42
PTH
(15.00–65.00 pg/mL) 74.37 18.87
Urine collection calcium
(100.0–320.0 mg/24h) 571
Urine collection phosphorus
(0.4–1.3 g/24h) 1.0
ACTH — adrenocorticotropic hormone; TSH — thyroid-stimulating hormone; 
PTH — parathormone; FT4 — free thyroxine; FT3 — free triiodothyronine
Figure 1. Ultrasound scan of the neck depicting parathyroid 
adenoma
drugs ruled out both Graves’ disease relapse and adrenal 
dysfunction (Tab. 1). Unexpectedly, we discovered elevated 
concentration of total calcium. Other tests were performed 
(Tab. 1). They disclosed raised PTH secretion, hypercalciuria 
and normal values of phosphorus in the blood and serum. 
Oral hydration was recommended. 
In following weeks, the concentration of PTH, total and 
ionized calcium were stable, but a decrease in phosphorus in 
the serum was noticed (2.57 mg/dL). Corrected calcium levels 
were 11.35 mg/dL. Ultrasonography of the abdomen revealed 
nephrolithiasis. We performed ultrasonography of the neck 
which disclosed a hypoechoic region 10 × 6 × 12 mm under 
the left thyroid lobe which could be consistent with enlarged 
parathyroid gland (Fig. 1). Basing on those results, the patient 
was operated. Surgery was done in the 24th gestation week. 
The procedure was modified mini invasive parathyroid gland 
adenoma excision. Because of the pregnancy, we did not 
use radionuclide guidance. The adenoma of the left inferior 
parathyroid was successfully dissected and removed. Frozen 
section pathology and intraoperative PTH assay supported 
the diagnosis of parathyroid adenoma. A postoperative PTH 
and calcium evaluation confirmed a curative procedure and 
the patient was dismissed home on the 3rd postoperative day 
(Tab. 1). The remainder of her pregnancy was uncomplicated. 
The women gave birth to a healthy baby girl in the 40th week 
of gestation. The child did not present any symptoms or 
abnormal biochemical changes. Apgar scale was 10 in the 
first and third minute after delivery. The mother visits regu-
larly Endocrinology Outpatient Clinic. The general condition 
of the patient is very good. Abnormalities in calcium and 
thyreotropin levels are not observed.
Second patient
A 28-years-old patient was admitted to the Outpatient 
Endocrinology Clinic due to hypercalcemia. The women 
presented previous test results from 18 months before. 
The concentration of total calcium was increased in every 
sample (Tab. 2). Medical history revealed miscarriage in the 
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9th week of pregnancy. In that time, the calcium levels were 
also high. She did not suffer from any other diseases nor 
took any medications. Her family history did not revealed 
any significant facts. On the day of the visit in the Endocri-
nology Outpatient Clinic ultrasonography of the neck was 
conducted. Under the left thyroid lobe we depicted a hypo-
echoic region 11 × 9 × 8 mm which could be consistent with 
an enlarged parathyroid gland. Test results were as follows 
(Tab. 2). Technetium-99m sestamibi showed an adenoma 
in the left inferior parathyroid. The patient was referred to 
the surgical ward in order to remove the lesion. Frozen sec-
tion pathology and intraoperative PTH assay confirmed the 
diagnosis of parathyroid adenoma and curative procedure. 
DISCUSSION
Changes in the calcium-phosphorus balance  
in pregnancy
The maternal organism undergoes adaptation to pro-
vide resources for the developing child. It also concerns 
the calcium-phosphorus balance. The increased calcium 
demand is fulfilled by greater absorption in the bowels, kid-
neys and a higher intake of this microelement [8]. Vitamin D 
concentration doubles in the early pregnancy and remains 
on the same level to term. The fetus allocates about 30 mg of 
calcium in its bones. Deposition occurs especially in the third 
trimester, during mineralization. Transport of calcium via 
placenta in the 1st and 2nd trimester is scarce. Total calcium 
levels are lower, mostly due to hemodilution, decreased 
albumin concentration and expanded fluid intravascular 
volume. Ionized calcium and phosphorus concentration 
remains unchanged. From the 12th gestation week the urinal 
excretion of calcium rises and exceeds normal values. PTH 
levels are in the low normal range in the first trimester (10–
–30% of mean values for non-pregnant women) and slowly 
rise to achieve mid-normal at the moment of labour [9]. 
A vital role in calcium metabolism is played by PTHrP 
(parathormone related protein). Its concentration greatly 
increases, especially towards the end of pregnancy. PTHrP 
is produced in several maternal organs, but also by fetal 
parathyroid glands. It is postulated that this protein regu-
lates the transport of calcium via placenta to the child and 
protects the mother’s skeleton from demineralization [10].
The knowledge of calcium-phosphorus balance in fe-
tus is scarce. Parathyroid glands originate from the third 
and fourth parapharyngeal pouch. They differentiate at 
the 5th–6th gestational week [11]. The fetal calcium concen-
trations are up to 0.5 to mg/dL higher than the mother’s, 
probably in order to prevent neonatal tetany and support 
mineralization. Also, the phosphorus levels are greater [12]. 
Maternal PTH does not cross the placenta (as well as cal-
citonin), but the fetal parathyroids are probably able to 
synthetize it since the 10th week. While the concentration 
of PTH and vitamin D in blood is low, the concentration of 
calcitonin and PTHrP is high. PTHrP facilitates, relatively 
independently of the maternal serum calcium levels, the 
ability of the fetal-placental unit to extract calcium. The 
secretion of the baby’s PTH can be regulated by both the 
mother’s and its own calcium levels. Elevated calcium in the 
mother’s blood can suppress the fetal parathyroid, while 
maternal hypocalcemia was described to be associated 
with secondary hyperparathyroidism in neonates [9]. Little 
is known about the role of the organs normally involved in 
regulating the calcium-phosphorus balance in adults during 
embryogenesis. Kidneys are involved in calcium metabolism 
via the production of small amounts of calcitriol and the 
regulation of minerals circulation. Intestines probably do 
not play a vital role [13]. The main purpose of alteration in 
the maternal mineral metabolism is to support the bone 
formation in the child. Primary ossification centers develop 
at the turn of the first and second trimester, but mineraliza-
tion mainly occurs in the third one [14]. What is important, 
the fetal skeleton participates in the calcium-phosphorus 
balance, which means that it is subjected to all the maternal 
disorders concerning mineral metabolism.
Symptoms and complications
As mentioned before, the symptoms of PHP are vague. 
Our first patient complained only about weakness, vertigo 
and stomach pain. The second one was diagnosed with 
PHP after a miscarriage which is described as a possible 
complication of PHP. 
Typical manifestations are called „bones, stones, ab-
dominal moans and psychic groans” which can be explained 
by bony fractures nephrolithiasis, gastritis and mental status 
changes. Besides those, many other symptoms, such as 
hypertension, polydipsia, polyuria, confusion, pancreati-
tis, could occur [2]. In pregnancy, the presentation of PHP 
Table 2. Results of the laboratory investigations for the second 
patient
Before 
pregnancy
6th week of 
pregnancy
After 
miscarriage
Calcium total
(8.80 – 10.20 mg/dL) 10.861 11.39 11.1
Phosphorus serum
(2.70–4.50 mg/dL) 2.57
Urine collection calcium
(100.0–320.0 mg/24h) 588
Urine collection 
phosphorus
(0.4–1.3 g/24h)
0.94
PTH
(15.00–65.00 pg/mL) 109
PTH — parathormone
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may be even more confusing. It was shown that hyper-
calcemia induces preeclampsia [6]. Moreover, Hultin et al. 
determined that it was particularly parathyroid adenoma 
that was associated with a higher risk of such complication. 
The authors suggested that both the entities were linked 
to insulin resistance and increased cardiovascular risk, thus 
the association might not be incidental [15]. PHP possibly 
leads to miscarriage with a 3.5 fold greater risk of such 
event. Norman et al. examined 78 pregnancies in women 
with elevated serum calcium levels due to PHP. They no-
ticed 30 miscarriages, especially at the turn of the first and 
second trimester. Most pregnancy cessations occurred with 
maternal calcium levels above 11.4 mg/dL. Increasing hyper-
calcemia was significantly associated with fetal loss rate [16]. 
Taking into account those studies and lack of serious ill-
nesses in the second case we described, we hypothesize that 
pregnancy loss in that woman might be attributed to PHP. 
On the other hand, in a recently published study by Hirsch 
et al., PHP was not significantly associated with increased 
rates of abortion or maternal complications. The authors 
retrospectively reviewed the charts of 74 women who were 
pregnant while being hypercalcemic. After comparing their 
pregnancy outcomes with normocalcemic controls, they 
did not find significant differences. Subsequently, the re-
searchers analyzed the possible existence of variations in 
the rate of pregnancy-related complications in women who 
underwent parathyroidectomy and those who did not. The 
operation was not associated with a lower incidence of abor-
tion or other side-effects of hypercalcemia. What is more, 
the authors did not disclose a correlation between calcium 
concentration and complication rates. However, it might be 
a result of considerably low calcium levels in the cohort [17]. 
The experienced nausea, dehydration and mental status 
changes point to the most threatening consequence of 
PHP which is a hypercalcemic crisis. It may occur during 
pregnancy, but also after delivery, when active transport 
of calcium (maternal-fetal gradient is 1:1.4) via placenta 
abruptly stops [18]. 
Fetal complications are present, as it was described 
before, in up to 80% of cases. The death of progeny was 
reported in even 27–31% of the cases. Other adverse effects 
are intrauterine growth retardation and low birth weight [7]. 
On the other hand, Abood et al. investigated 1057 women 
with PHP and compared their pregnancy outcomes with 
those of 3171 healthy ones. They did not disclose significant 
differences between the neonate birth weight, length and 
Apgar score [19]. Elevated levels of maternal calcium and 
active transport of this microelement to the baby lead to 
the suppression of the fetal parathyroid. After labor, when 
calcium delivery is cut off, the neonate experiences tetany. 
Although hypocalcemia is usually transient, there were re-
ports of prolonged or permanent illness in children. It was 
attributed to the adverse effect of hypercalcemia on the 
third and fourth brachial clefts during organogenesis [20]. 
To sum up, complicated, symptomatic PHP could pose 
a threat for the mother and the child’s life, unless a proper 
treatment is introduced.
Diagnosis
Due to changes which occur in pregnancy (Tab. 3), the 
diagnosis of PHP is a real challenge for the clinician. This 
could be a reason for the delayed or missed introduction 
of the treatment. It is perfectly illustrated by cases we pre-
sented. In the study by Norman et al. PHP goes undiagnosed 
in up to 50% of pregnant women. Those results were consist-
ent with a research by Hirsch et al. The mean interval from 
first detection of hypercalcemia to the measurement of PTH 
was approximately 43 months [17]. The value of the assess-
ment of PTH and total calcium is limited due to physiological 
decrease in their concentration during pregnancy. Corrected 
or ionized calcium should be measured. The formula for 
calculating the corrected calcium is given below. 
Corrected Ca (mmol/L) = Ca mmol/L + (0.02 × (40‐al-
bumin g/L))
 An increase in corrected or ionized calcium levels to-
gether with PTH above or within high normal range in 
pregnant women, points to PHP. Other possible reasons of 
hypercalcemia need to be excluded [21]. After diagnosis, 
a parathyroid disease should be localized. Routinely em-
ployed imaging modalities, namely computed tomography 
and sestamibi scintigraphy, are to be avoided in pregnancy. 
The first one due to the exposition to radioactive technetium, 
the second because of the Röntgen radiation. In this setting, 
an ultrasonography of the thyroid gland becomes the most 
important tool to localize a parathyroid lesion [22]. Despite 
the fact that it has 69% sensitivity and 94% specificity in 
diagnosing an adenoma of the parathyroid, the procedure 
is highly operator-dependent [23]. To increase the accuracy 
of the diagnosis, an ultrasound-guided fine needle aspiration 
biopsy (FNAB) of the suspected lesion may be performed. 
Table 3. Changes in the calcium homeostasis during pregnancy
Measured levels Pregnant woman
Serum calcium Total ↓Ionized ↔
Urinary calcium ↑
PTH ↓↔
PTHrP Progressively ↑
25‐vitamin D ↔
1.25‐dihydroxyvitamin D Progressively ↑
Calcitonin ↑
PTH — parathormone; PTHrP — parathormone related protein
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However, it is hard to distinguish thyroid from parathyroid 
cells by means of cytological examination [24]. PTH levels 
from needle washouts can be measured. Abraham et al. 
examined 34 specimens from non-pregnant patients with 
suspected PHP and compared it with samples from thyroid 
nodules. PTH levels were significantly higher in PHP than in 
thyroid lesions. Moreover, the specificity (95%) and sensitiv-
ity (91%) were very promising [25]. To our knowledge, there 
are no studies concerning PTH concentrations from FNAB in 
pregnant women, but it is a safe procedure, when performed 
by an experienced clinician. There are only few absolute con-
traindications to FNAB, namely uncorrectable coagulopathy 
or platelet disorder. PHP should be also suspected when the 
patient suffers from nephrolithiasis, pancreatitis, hyperemesis, 
has a history of miscarriage or neonatal problems of progeny 
with calcium levels. 
Treatment
Optimal management is a matter of debate. The con-
servative treatment encompasses hydration, oral phos-
phates, diuretics and low calcium diet. First line proceeding 
in mild cases should be adequate fluid intake. Parathyre-
oidectomy or treatment with calcitonin, calcimimetic and 
bisphosphates are reserved for more serious cases.
Bisphosphates are contraindicated because they cross 
the placenta and may be associated with fetal skeletal ab-
normalities, reduced bone growth, weight restriction or 
hypocalcemia at birth [26]. Losada et al. demonstrated a 20% 
rate of congenital abnormalities in children who were ex-
posed to bisphosphates during fetal life [27]. It is possible 
that above abnormalities will occur even if the mother had 
received oral bisphosphates before pregnancy [28]. They are 
retained in the mother’s skeleton, so this treatment must be 
stopped long before the conception [26, 28]. On the other 
hand, there are data indicating that bisphosphates do not 
cause serious adverse events [26]. However, the risk is high, 
so bisphosphates should not be used in this period.
Calcimimetics has not been widely used in pregnancy. 
There are only three cases described in literature [29–31]. In 
two of them, cinacalcet was given only for two weeks before 
the delivery. The third women, who suffered from parathy-
roid carcinoma, received cinacalcet throughout pregnancy. 
Despite the fact that no adverse effects occurred, it is un-
known whether cinacalcet is safe for the fetus. 
Although calcitonin does not cross the placenta, it is not 
consider completely safe in this period of a woman’s life [32]. 
Furthermore, calcitonin has limited effect.
 Some authors claim that asymptomatic patients with 
mild hypercalcemia (< 12 mg/dL) could be treated without 
a surgical intervention. Though, such a method requires 
close medical attention throughout a long period of time. 
If the mother becomes symptomatic or hypercalcemia 
aggravates, a surgery is recommended regardless of the 
gestational age [19]. On the other hand, fetal and maternal 
complications are difficult to predict basing on the serum 
calcium levels in the mother. It remains unknown, if mildly 
elevated calcium levels cause the same rate of complications 
as higher ones. While other forms of treatment should be 
taken into account, an operation in the second trimester 
is still considered the ‘gold standard’. Many authors have 
proved significant reduction of the adverse effects of PHP 
when operation was conducted, in comparison to the con-
servative treatment. A review which compares surgery to 
other treatment methods, has shown the incidence of neo-
natal complications 10% vs. 37% , and neonatal mortality 3% 
vs. 16% [33]. Moreover, minimally invasive parathyroidec-
tomy, which is of the same effectiveness as bilateral neck dis-
section, may be performed. The first method is characterized 
by a limited operation region, shorter hospitalization time 
and a smaller scar, as compared to the second one. Thus, it 
is associated with greater safety and the patient’s satisfac-
tion [34]. On the other hand, it should be mentioned that 
surgery could be dangerous for both the woman and her 
progeny. A first-trimester operation is to be avoided due to 
incomplete organogenesis and possible teratogenic effect 
of anesthetics. A third-trimester surgical treatment poses 
a risk of pre-term delivery [35]. In both our patients, the op-
eration was finally performed, without any adverse effects.
To conclude, calcium levels should be assessed in pregnant 
women and in those who have a history of miscarriage. PHP 
could be suspected when ionized or corrected calcium levels 
are elevated, while PTH might be within normal range. While 
computed tomography and sestamibi scintigraphy are to be 
avoided in pregnancy, an ultrasound scan of the neck should 
be performed to localize the lesion. When needed, surgery is 
recommended in the second trimester of pregnancy. Deci-
sion concerning the method of treatment should be made 
by assessing both the clinical status and biochemical blood 
results. When a conservative treatment is introduced, the 
mother and her child should remain under strict control. Tak-
ing into account possible adverse effect of PHP on the health of 
both the woman and the fetus, there are growing pro-surgery 
evidence, regardless of gestational age, but randomized mul-
ti-institutional studies are needed to clarify this issue. 
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